2 to 3 minutes
A result during the appointment, not a week later.
DETRHO
Anti-D screening, during the prenatal visit
HOME › SERVICES & PRODUCTS › DETRHO
MATERNAL HEALTH
One drop of blood.
The result at the point of care.
One strip, one drop of blood, a result in 2 to 3 minutes. DETRHO is designed to tell the clinician, during the appointment, whether an Rh-negative pregnant woman is already immunized against the Rh factor.
T
C
D E T R H O
Concept visual in development
→Partner with us on validationIn development · Not yet licensed for clinical use
How it works ↓In development · Not yet licensed for clinical use
Explore the two animations →THE PROBLEM
A week for an answer that should fit in a single appointment
When a mother is Rh-negative and her baby is Rh-positive, her body can produce anti-D antibodies. These antibodies cross the placenta and attack the baby’s red blood cells. This is hemolytic disease of the fetus and newborn, and it can also affect future pregnancies. Caught in time, it can be prevented.
Mother’s blood · Rh−
Baby’s blood · Rh+
PLACENTA
1 Mother Rh−, baby Rh+
2 She produces anti-D antibodies
3 They attack the baby’s red blood cells
In development. Not yet licensed for clinical use.
Today, testing for these antibodies means a venous blood draw, shipping to a reference lab and several days of waiting. In remote regions, that means repeat visits, lost follow-ups and decisions made without the information.
Today
1. Venous draw at the clinic 2. Shipping to a reference lab 3. Several days before the result
With DETRHO One drop of blood, 2 to 3 minutes, on site.
In development · Not yet licensed for clinical use
2 to 3 minutes
One drop of blood
No reader
Design objectives under validation. Not yet licensed for clinical use.
WHAT DETRHO CHANGES
The result arrives where the decision is made
One drop of blood
Whole blood or plasma. No venous sample to ship.
No equipment
No reader, no centrifuge, no specialized lab staff.
Strip format
Single use, as simple to run as a pregnancy test.
Targeted detection
Only the anti-D antibody is captured, not all the immunoglobulins in the blood.
In development · Not yet licensed for clinical use
03 / HOW IT WORKS
Follow the drop.
2 to 3
minutes
Design target under validation
1 One drop whole blood, fingerstick
2 Anti-D capture test line
3 Read by eye control line
T
C
Illustrative T/C lines. No patient result or clinical decision.
In development. Not yet licensed for clinical use.
DETRHO is built on a lateral flow bridging immunoassay. When present, the anti-D antibody binds the RhD antigen at two points at once. That double link is what makes the test specific.
Reading the result
C line only: valid test, no anti-D antibodies detected. C and T lines: anti-D antibodies present. No C line: invalid test, repeat.
In development · Not yet licensed for clinical use
WHO IT IS FOR
Designed first for settings far from a lab
Regional clinics
Rural, remote and northern settings, where every trip counts.
Hospitals and perinatal care
Pregnancy follow-up units that want an answer at the first visit.
Public health
Maternal health programs and primary care networks.
Canada and West Africa
Wherever access to screening is limited outside major centres.
In development · Not yet licensed for clinical use
05 / WHERE WE ARE
Validation, one step at a time
We will share the results of each step. No performance data will be published until validation is complete.
In development. Not yet licensed for clinical use.
01
Laboratory proof of concept
Completed
02
Validation on real blood samples
Fall 2026
03
Clinical performance evaluation
Upcoming
04
Regulatory review and licensing
Upcoming
06 / QUESTIONS
DETRHO FAQ
What exactly does DETRHO detect?
Anti-D antibodies (anti-RhD immunoglobulins) in a pregnant woman’s blood. Their presence shows that the mother is already immunized against the Rh factor.
Is DETRHO available?
Not yet. DETRHO is an in vitro diagnostic device in development. It is not licensed, it is not used for clinical decisions and no results are returned to patients.
Will DETRHO replace laboratory testing?
DETRHO is designed as a point-of-care screening test. Clinical decisions remain with healthcare professionals and follow current guidelines, including confirmatory laboratory testing.
Can recent anti-D prophylaxis affect the result?
As with current serological methods, anti-D given as prophylaxis can be detected in the blood. Interpretation must therefore take the patient’s prophylaxis history into account.
How can I follow the project?
Follow Bioeureka on LinkedIn or write to us to receive our updates. We share every step of the validation.
In development. Not yet licensed for clinical use.
Help us validate DETRHO
Are you with a healthcare facility, a laboratory, a maternal health program or a distributor? Write to us to take part in validation or to follow DETRHO’s arrival in your region.
→Contact usIn development. Not yet licensed for clinical use.
Biōeureka™
DETRHO is an in vitro diagnostic device in development. It is not licensed by Health Canada or any other regulatory authority and is not offered for sale or for clinical use.
MATERNAL HEALTH
DETRHO
Anti-D screening, during the prenatal visit
One strip, one drop of blood, a result in 2 to 3 minutes. DETRHO is designed to tell the clinician, during the appointment, whether an Rh-negative pregnant woman is already immunized against the Rh factor.
T
C
D E T R H O
Concept visual in development
In development · Not yet licensed for clinical use
THE PROBLEM
A week for an answer that should fit in a single appointment
When a mother is Rh-negative and her baby is Rh-positive, her body can produce anti-D antibodies. These antibodies cross the placenta and attack the baby’s red blood cells. This is hemolytic disease of the fetus and newborn, and it can also affect future pregnancies. Caught in time, it can be prevented.
Mother’s blood · Rh−
PLACENTA
Baby’s blood · Rh+
1 Mother Rh−, baby Rh+
2 She produces anti-D antibodies
3 They attack the baby’s red blood cells
Today, testing for these antibodies means a venous blood draw, shipping to a reference lab and several days of waiting. In remote regions, that means repeat visits, lost follow-ups and decisions made without the information.
Schematic illustration. Scientific content to be validated; no diagnosis or treatment recommendation.
In development. Not yet licensed for clinical use.
Today
1. Venous draw at the clinic 2. Shipping to a reference lab 3. Several days before the result
With DETRHO One drop of blood, 2 to 3 minutes, on site.
In development · Not yet licensed for clinical use
2 to 3
minutes
Design objective
One drop
Whole blood
or plasma
No reader
Strip format
In development. Not yet licensed for clinical use.
WHAT DETRHO CHANGES
The result arrives where the decision is made
2 to 3 minutes
A result during the appointment, not a week later.
One drop of blood
Whole blood or plasma. No venous sample to ship.
No equipment
No reader, no centrifuge, no specialized lab staff.
Strip format
Single use, as simple to run as a pregnancy test.
Targeted detection
Only the anti-D antibody is captured, not all the immunoglobulins in the blood.
In development · Not yet licensed for clinical use
02 / HOW IT WORKS
From one drop
to the strip.
DETRHO is built on a lateral flow bridging immunoassay. When present, the anti-D antibody binds the RhD antigen at two points at once. That double link is what makes the test specific.
2 to 3
minutes
1 One drop whole blood, fingerstick
Design objective
T
C
2 Anti-D capture test line
3 Read by eye control line
ILLUSTRATIVE C + T SEQUENCE
No patient result or clinical decision.
In development. Not yet licensed for clinical use.
Reading the result
C line only: valid test, no anti-D antibodies detected. C and T lines: anti-D antibodies present. No C line: invalid test, repeat.
In development · Not yet licensed for clinical use
03 / WHO IT IS FOR
Designed first for settings far from a lab
Designed first for settings where access to screening is limited.
Regional clinics
Rural, remote and northern settings, where every trip counts.
Hospitals and perinatal care
Pregnancy follow-up units that want an answer at the first visit.
Public health
Maternal health programs and primary care networks.
Canada and West Africa
Wherever access to screening is limited outside major centres.
In development. Not yet licensed for clinical use.
04 / WHERE WE ARE
Validation, one step at a time
01
Laboratory proof of concept
Completed
02
Validation on real blood samples
Fall 2026
03
Clinical performance evaluation
Upcoming
04
Regulatory review and licensing
Upcoming
We will share the results of each step. No performance data will be published until validation is complete.
In development. Not yet licensed for clinical use.
In development · Not yet licensed for clinical use
05 / YOUR QUESTIONS
DETRHO FAQ
What exactly does DETRHO detect?
Anti-D antibodies (anti-RhD immunoglobulins) in a pregnant woman’s blood. Their presence shows that the mother is already immunized against the Rh factor.
Is DETRHO available?
Not yet. DETRHO is an in vitro diagnostic device in development. It is not licensed, it is not used for clinical decisions and no results are returned to patients.
Will DETRHO replace laboratory testing?
DETRHO is designed as a point-of-care screening test. Clinical decisions remain with healthcare professionals and follow current guidelines, including confirmatory laboratory testing.
Can recent anti-D prophylaxis affect the result?
As with current serological methods, anti-D given as prophylaxis can be detected in the blood. Interpretation must therefore take the patient’s prophylaxis history into account.
How can I follow the project?
Follow Bioeureka on LinkedIn or write to us to receive our updates. We share every step of the validation.
In development. Not yet licensed for clinical use.
BUILD THE NEXT STEP WITH US
Help us validate DETRHO
Are you with a healthcare facility, a laboratory, a maternal health program or a distributor? Write to us to take part in validation or to follow DETRHO’s arrival in your region.
Contact us→In development. Not yet licensed for clinical use.
Biōeureka™
DETRHO is an in vitro diagnostic device in development. It is not licensed by Health Canada or any other regulatory authority and is not offered for sale or for clinical use.